Menstrual blood derived mesenchymal stem cell therapy - S-Evans

Drug Profile

Menstrual blood derived mesenchymal stem cell therapy - S-Evans

Alternative Names: C'elle menstrual stem cells; Human menstrual blood derived mesenchymal stem cell therapy - S-Evans; MenSC

Latest Information Update: 20 May 2015

Price : $50

At a glance

  • Originator Cryo-Cell International
  • Developer S-Evans Biosciences; Zhejiang University
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute lung injury; Liver cirrhosis; Type 1 diabetes mellitus

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top